Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Net Cash Flow (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Net Cash Flow for 7 consecutive years, with -$185.9 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 41.18% to -$185.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.7 million through Dec 2025, up 139.48% year-over-year, with the annual reading at $28.7 million for FY2025, 139.48% up from the prior year.
  • Net Cash Flow hit -$185.9 million in Q4 2025 for IDEAYA Biosciences, down from $184.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $217.2 million in Q3 2024 to a low of -$316.0 million in Q4 2024.
  • Historically, Net Cash Flow has averaged $2.1 million across 5 years, with a median of $1.9 million in 2023.
  • Biggest five-year swings in Net Cash Flow: surged 4539.07% in 2021 and later plummeted 6173.63% in 2024.
  • Year by year, Net Cash Flow stood at -$16.4 million in 2021, then crashed by 103.41% to -$33.3 million in 2022, then soared by 115.61% to $5.2 million in 2023, then tumbled by 6173.63% to -$316.0 million in 2024, then skyrocketed by 41.18% to -$185.9 million in 2025.
  • Business Quant data shows Net Cash Flow for IDYA at -$185.9 million in Q4 2025, $184.3 million in Q3 2025, and -$15.4 million in Q2 2025.